Orin
EMNNYSE·Chemicals - Specialty

Eastman Chemical Company

Market cap $7.6BP/E 17.1× trailingGross margin 19.9%
$66.12
+0.39 (+0.59%)Tue 27 Oct close 16:00 ET
52-wk $56.11 – $83.47
Orin's take
6out of 10 — how sure Orin is of this read

Orin's own judgment of how firmly the evidence points one way — not the chance the price goes up.

Refreshed 9 Oct, the 5th take on EMN. A new filing or a print queues the next refresh.

Eastman Chemical's Q2 2026 results showed a genuine cyclical inflection — revenue grew 9.9% YoY to $2.51B and EPS recovered to $1.59, beating consensus by 8.2% — but the stock has since fallen to $62.69, well below both its 50-day ($69.54) and 200-day ($71.10) moving averages with an RSI of 32.7 signaling oversold conditions.

FY2025 was a trough year with revenue down 6.7% to $8.75B, gross margin compressed to 21.1% from 24.4% in FY2024, and EPS falling 46.5% to $4.10, so one strong quarter does not yet confirm a durable recovery. The 16.2x PE and 0.81x PS discount peers by 20.5% and 54.2% respectively, but the market is pricing in continued cyclical risk and the technical downtrend remains unbroken.

What could go wrong

  • Cyclical demand deterioration. FY2025 revenue fell 6.7% YoY and net income dropped 47.6%; if Q2 2026's 9.9% revenue growth does not sustain into H2, the recovery thesis breaks.
  • Margin compression persistence. Gross margin contracted from 24.4% in FY2024 to 21.1% in FY2025; if input costs or pricing pressure prevent margin recovery, earnings power remains structurally lower.
  • Technical breakdown accelerates. Stock at $62.69 is below both the 50-day ($69.54) and 200-day ($71.10) moving averages with RSI at 32.7; further selling could signal deeper fundamental concerns.
  • High leverage in downturn. Total debt of $5.08B against stockholders' equity of $5.96B as of FY2025 limits financial flexibility if end-market demand weakens further.

What would change my mind

Q3 2026 results confirm recovery. Q3 2026 revenue grows YoY and operating margin expands toward FY2024's 14.7% levelbullish
Stock reclaims 50-day moving average. EMN closes above $69.54 on volume, breaking the downtrendbullish
Q3 2026 revenue reverts to decline. Q3 2026 revenue falls below prior-year Q3's $2.20B, reversing the Q2 inflectionbearish
Gross margin fails to recover. Quarterly gross margin remains at or below FY2025's 21.1% level, indicating structural cost pressurebearish

Where this comes from: Q2 2026 results · earnings vs estimates, 30 Jul · FY25 fundamentals · technicals, 9 Oct. Orin's read on EMN; not advice.

How has the share price moved?

27 Oct 2025 – 27 Oct 2026

Up 3.7% over twelve months, from $63.78 on 27 Oct 2025 to $66.12 at the Tue 27 Oct 2026 close. Its highest close in that time was $81.36 on 11 Feb 2026; the last close is 18.7% below it.

Jan 2026AprJulOct
    • Green line: the closing price each trading day.
    • Grey line: the average closing price over the last 50 trading days.
    • Dashed amber line: the same over the last 200 trading days — a slower, smoother line.
    • Bars along the bottom: shares traded each day — green when it closed higher than the day before, rose when lower (the most, 30.0M, on 3 Nov 2025).
    • Flags: the company's filings, on the day they were made (a 10-Q is the quarterly report and a 10-K the annual report; an 8-K reports a major event).

    Largest holders · 13F Q2 2026

    Money flow
    FilerPositionOf fund
    BlackRock$1.1B0.0%
    Vanguard Portfolio Management$506.0M0.0%
    Vanguard Capital Management$345.6M0.0%
    State Street$282.7M0.0%
    Morgan Stanley$223.1M0.0%
    Franklin Resources$192.4M0.0%
    Massachusetts Financial Services$178.4M0.1%
    Bank of America$165.4M0.0%
    Earnest Partners$160.9M0.6%
    Capital Research Global Investors$146.7M0.0%

    77 of the 815 filers we track · quarter ended Q2 2026 · positions, not flows

    Insiders, last 24 months: 104 Form 4 filings; open-market trades net −$246K. Of the 50 on hand, 0 were open-market purchases and 2 sales — the rest are grants, option exercises and tax withholding.

    Ask Orin about EMN

    its filings · its transcripts · its numbers

    Orin answers questions about EMN from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

    Start 3 free days →

    How is it priced, against its own past and its sector?

    Tue 27 Oct close

    Priced at 17.1× its last 12 months of profit (Tue 27 Oct close) — higher than in 4 of its last 5 fiscal years (middle 12.7×); the typical Basic Materials company on the NYSE is at 22.4×.

    MeasureNowIts usualSector
    P/E17.1×above usual12.7×22.4×
    P/S0.85×below usual1.14×—
    EV/EBITDA9.5×above usual9.0×—
    P/B1.2×below usual2.0×—
    • "Its usual" is the middle of its own last 5 fiscal years.

    P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.

    P/S: the company's total market value divided by one year of revenue. Used when there is no profit to measure.

    EV/EBITDA: the price of the whole company (its shares plus its debt, minus its cash) divided by one year of operating profit before interest, tax and write-downs.

    P/B: the share price divided by the book value per share — what the company owns minus what it owes, as its accounts record it. When book value is tiny, P/B swings wildly and says little.

    What do the analysts who cover it publish?

    12 firms rated it in the last 18 months · 27 Oct

    The analysts' average 12-month price target is $76.89 (from $68 to $85) — 16% above the Tue 27 Oct close price. That is their published opinion, not Orin's.

    Average price target

    $76.89

    $68 – $85 · +16% against the last close

    Their ratings
    • 6 buy or overweight
    • 6 hold
    • 0 underweight or sell

    Price target: the share price an analyst publishes for about 12 months ahead. It is the opinion of the firm that wrote it; the average is across the firms that cover the company.

    Overweight / underweight: analysts' rating words: overweight means the firm expects the stock to do better than the others it covers, underweight worse. Their words, not Orin's.

    How is it priced next to the companies it is compared to?

    middle P/E 29.4× · 6 of 10 with a profit

    Priced at 17.1× its last 12 months of profit; the middle P/E of the 6 companies it is compared to that made a profit is 29.4×.

    CompanyMarket valueP/EEV/EBITDAGross marginNet marginROE
    EMNEastman Chemical Company$8B17.1×9.5×19.9%5.0%7%
    ASHAshland Inc.$3B63.8×11.5×29.4%2.8%3%
    AVNTAvient Corporation$4B23.0×10.9×32.1%5.3%8%
    CBTCabot Corp.$4B20.5×7.0×22.9%5.2%12%
    DOWDow Inc.$24Blost money11.2×11.1%−1.9%−5%
    ESIElement Solutions Inc$9B41.4×22.3×36.6%5.9%7%
    HUNHuntsman Corporation$2Blost money13.4×13.5%−2.9%−6%
    IOSPInnospec Inc.$2B20.4×12.5×27.5%6.6%9%
    NGVTIngevity Corporation$2B35.8×17.2×42.0%5.3%134%
    SCLStepan Co$1Blost money13.0×11.8%−0.1%0%
    WLKWestlake Corporation$8Blost money18.2×5.9%−3.9%−5%
    • DOW, HUN, SCL, WLK: lost money over the last 12 months, so no P/E.
    • The list of companies is the data vendor's choice, so it can include a company a person would not have picked.

    Market value: the share price times the number of shares — what the whole company is priced at.

    P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.

    EV/EBITDA: the price of the whole company (its shares plus its debt, minus its cash) divided by one year of operating profit before interest, tax and write-downs.

    Gross margin: the share of each $1 of sales left after the direct cost of making what was sold.

    Net margin: the share of each $1 of sales kept as profit after every cost. Below zero, the company lost money.

    ROE: return on equity: one year of profit as a share of the shareholders' money in the business (its book value).

    Is it priced high or low compared with its own past?

    Tue 27 Oct

    Priced at 17.1× its last 12 months of profit (Tue 27 Oct close). It has no full fiscal year on file since its history starts, so there is nothing of its own to compare with.

    • Now17.1×

    P/E: the share price divided by one year of profit per share — roughly how many years of today's profit the price pays for. A company that loses money has no P/E.

    Fiscal year (FY): the company's own 12-month accounting year, which need not match the calendar year.

    How has its sector been priced?

    Now–Now · Tue 27 Oct

    Basic Materials companies on the NYSE were priced at a typical 22.4× their yearly profit (Tue 27 Oct close).

    • Now22.4×
    • Each year is the middle of that calendar year's daily sector P/E; "Now" is the Tue 27 Oct close figure, the same one in the table above.

    Sector P/E: the middle P/E of the companies in the same sector on the same stock exchange, as the data vendor works it out each day.

    What does a cash-flow model say a share is worth?

    computed 27 Oct at $66.18

    A standard cash-flow model puts it at $77 a share — 17% above the $66.18 price it was computed against (27 Oct).

    ModelValue a shareAgainst the price then
    Standard$7717% above $66.18
    Levered$3942% below $66.18

    Discounted cash flow: a model's estimate of what the company is worth today, from the cash it is forecast to make in future years. Small changes in the forecast move it a lot, and it says little about a company that loses money.

    Standard / levered: two versions of the cash-flow model: the standard one counts the cash before the company pays its lenders, the levered one after.